Search by Drug Name or NDC
NDC 66302-0206-01 TYVASO 1.74 mg/2.9mL Details
TYVASO 1.74 mg/2.9mL
TYVASO is a ORAL INHALANT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by United Therapeutics Corporation. The primary component is TREPROSTINIL.
MedlinePlus Drug Summary
Treprostinil oral inhalation is used to treat certain kinds of pulmonary arterial hypertension (PAH; high blood pressure in the vessels carrying blood to the lungs, causing shortness of breath, dizziness, and tiredness). Treprostinil oral inhalation is also used to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD; high blood pressure in the lungs resulting from a lung disease that involves inflammation and scarring of the lungs). Treprostinil may improve the ability to exercise and slow the worsening of symptoms in patients with PAH and PH-ILD. Treprostinil is in a class of medications called vasodilators and platelet-aggregation inhibitors. It works by relaxing the blood vessels, including those in the lungs, and improving blood flow.
Related Packages: 66302-0206-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Treprostinil Oral Inhalation
Product Information
| NDC | 66302-0206 |
|---|---|
| Product ID | 66302-206_793c8b90-98ca-4d44-9c88-d4df538f97e5 |
| Associated GPIs | 40170080002020 |
| GCN Sequence Number | 065500 |
| GCN Sequence Number Description | treprostinil/nebulizer/accesor AMPUL-NEB 1.74MG/2.9 INHALATION |
| HIC3 | B1C |
| HIC3 Description | PULMONARY ANTIHYPERTENSIVES, PROSTACYCLIN-TYPE |
| GCN | 27489 |
| HICL Sequence Number | 036537 |
| HICL Sequence Number Description | TREPROSTINIL/NEBULIZER AND ACCESSORIES |
| Brand/Generic | Brand |
| Proprietary Name | TYVASO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | treprostinil |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INHALANT |
| Route | ORAL |
| Active Ingredient Strength | 1.74 |
| Active Ingredient Units | mg/2.9mL |
| Substance Name | TREPROSTINIL |
| Labeler Name | United Therapeutics Corporation |
| Pharmaceutical Class | Prostacycline Vasodilator [EPC], Prostaglandins I [CS], Vasodilation [PE] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA022387 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 66302-0206-01 (66302020601)
| NDC Package Code | 66302-206-01 |
|---|---|
| Billing NDC | 66302020601 |
| Package | 1 BOX in 1 KIT (66302-206-01) / 28 AMPULE in 1 BOX / 2.9 mL in 1 AMPULE |
| Marketing Start Date | 2009-08-14 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |